0.000225794797687913 0.00230310693641627 0.0102510838150289 0.00943822254335262 -0.0139089595375722 -0.0145411849710983 -0.0322886560693642 -0.0224891618497109
Sign Up Today X
Thanks for submitting the form.
Stockreport

Crispr: Beyond Gene-Editing [Seeking Alpha]

Vertex Pharmaceuticals Incorporated (VRTX)  More Company Research Source: Seeking Alpha
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Summary In late 2019, the company published strong clinical results for two patients suffering from sickle cell disease and beta-thalassemia. Asides from gene-editing, Crispr is expanding into the lucrative CAR-T niche. Amid the Coronavirus bear market, you should consider Crispr for your portfolio. The largest profits in the investment field go to those who are capable of correctly zigging when the financial community is zagging. - Phillip Fisher Contrary to conventional wisdom, I strongly believe that now is an excellent time for you to pick up fundamentally-sound stocks. And when you invest in a bio stock, it's helpful to gauge the direction of a company. That includes both technical and fundamental fronts. In other words, you should develop a feeling (i.e., gut instinct) of which therapeutic area the management is aiming. After all, where a young company is positioning is crucial to its success. By taking a company into a lucrative arena like CAR-T, the management can unlock treme [Read more]
IMPACT SNAPSHOT EVENT TIME: VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
VRTX alerts
from News Quantified
VRTX
NEWS
VRTX
Earnings
VRTX
Analyst Actions
VRTX
SEC Filings
Stockreport

Crispr: Beyond Gene-Editing [Seeking Alpha]

Vertex Pharmaceuticals Incorporated  (VRTX) 
More Company Research Source: Seeking Alpha
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
Summary In late 2019, the company published strong clinical results for two patients suffering from sickle cell disease and beta-thalassemia. Asides from gene-editing, Crispr is expanding into the lucrative CAR-T niche. Amid the Coronavirus bear market, you should consider Crispr for your portfolio. The largest profits in the investment field go to those who are capable of correctly zigging when the financial community is zagging. - Phillip Fisher Contrary to conventional wisdom, I strongly believe that now is an excellent time for you to pick up fundamentally-sound stocks. And when you invest in a bio stock, it's helpful to gauge the direction of a company. That includes both technical and fundamental fronts. In other words, you should develop a feeling (i.e., gut instinct) of which therapeutic area the management is aiming. After all, where a young company is positioning is crucial to its success. By taking a company into a lucrative arena like CAR-T, the management can unlock treme [Read more]
IMPACT SNAPSHOT
EVENT TIME:
VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS